New Japanese rubella vaccine: comparative trials.
A total of 142 seronegative volunteers were given one of the following rubella vaccines: Cendehill, HPV77. DE-5, RA27/3, or a new Japanese vaccine, To-336. To-336 vaccine produced a slightly higher geometric mean antibody titre (G.M.T.) (65.7) than did the HPV77. DE-5 (63.1) or RA27/3 vaccine (61.9) but the G.M.T. induced by Cendehill vaccine was much lower (39.3).Reactions, particularly joint symptoms, occurred least commonly after vaccination with To-336 vaccine. Joint symptoms occurred within seven days of menstruation in 30 out of 37 (81%) vaccines (P <0.01); their incidence was not related to oral contraception.Though there is evidence to suggest that Japanese virus strains may be non-teratogenic further data on the incidence of congenitally acquired infection in Japan must be collected before this conclusion can be supported on epidemiological grounds.
D000914:Antibodies, Viral / Q000032:analysis; D002986:Clinical Trials as Topic; D005260:Female; D006386:Hemagglutination Tests; D006801:Humans; D007564:Japan; D007592:Joint Diseases / Q000209:etiology; D008131:London; D009305:Nasopharynx / Q000032:analysis; D012409:Rubella / Q000276:immunology*; D012411:Rubella Vaccine / Q000009:adverse effects; D012412:Rubella virus / Q000302:isolation & purification; D012871:Skin Diseases / Q000209:etiology; D014611:Vaccination
D000914:Antibodies, Viral; D012411:Rubella Vaccine